PainChek secures major US deal with Sabra REIT

PainChek (ASX:PCK) announced a master services agreement with Sabra Health Care REIT (NASDAQ:SBRA), a heavyweight in the North American healthcare real estate market.

The landmark deal will see Sabra, a $5 billion Nasdaq-listed entity, fund the deployment of PainChek's AI-powered pain assessment solution across its extensive portfolio, initially targeting up to 20,000 beds across 329 skilled nursing and senior housing facilities in the United States and Canada.

The agreement serves as a critical commercial milestone following PainChek’s 2025 FDA approval.

Under the perpetual contract, Sabra will subsidise the technology costs for its operating partners, effectively removing financial barriers and streamlining the adoption of digital pain monitoring.

Pricing is set between US$55 and US$75 per bed per annum, with incentives for long-term commitments or collaborative research participation.

Industry analysts view this owner-led distribution model as a "capital-light" go-to-market strategy that reduces sales cycles.

By securing endorsement at the REIT level, PainChek gains immediate access to a vast network of operators without the traditional overhead of individual facility marketing.

With Sabra managing over 36,000 units across North America, the partnership provides a scalable blueprint that PainChek intends to replicate with other institutional asset owners, cementing its position as a global leader in AI-driven geriatric care.

At the time of reporting, PainChek’s share price was $0.18.